ResMed Inc. Logo

ResMed Inc.

RMD

(2.8)
Stock Price

243,08 USD

26.94% ROA

21.21% ROE

28.58x PER

Market Cap.

25.913.197.640,00 USD

35.19% DER

1.04% Yield

20.4% NPM

ResMed Inc. Stock Analysis

ResMed Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ResMed Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (22.59%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a minimal amount of debt (35%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend Growth

Investors can be encouraged by the company's strong dividend growth over the past five years, highlighting its ability to generate consistent returns and provide an attractive investment opportunity.

5 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (785), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.15x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

ResMed Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ResMed Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

ResMed Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ResMed Inc. Revenue
Year Revenue Growth
1993 7.700.000
1994 13.900.000 44.6%
1995 23.500.000 40.85%
1996 34.600.000 32.08%
1997 49.200.000 29.67%
1998 66.500.000 26.02%
1999 88.600.000 24.94%
2000 115.615.000 23.37%
2001 155.156.000 25.48%
2002 204.076.000 23.97%
2003 273.570.000 25.4%
2004 339.338.000 19.38%
2005 425.505.000 20.25%
2006 606.996.000 29.9%
2007 716.332.000 15.26%
2008 835.397.000 14.25%
2009 920.735.000 9.27%
2010 1.092.357.000 15.71%
2011 1.243.148.000 12.13%
2012 1.368.515.000 9.16%
2013 1.514.457.000 9.64%
2014 1.554.973.000 2.61%
2015 1.678.912.000 7.38%
2016 1.838.713.000 8.69%
2017 2.066.737.000 11.03%
2018 2.340.196.000 11.69%
2019 2.606.572.000 10.22%
2020 2.957.013.000 11.85%
2021 3.196.825.000 7.5%
2022 3.578.127.000 10.66%
2023 4.222.993.000 15.27%
2024 3.852.148.000 -9.63%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ResMed Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 2.800.000 100%
1997 3.800.000 26.32%
1998 5.000.000 24%
1999 6.500.000 23.08%
2000 8.499.000 23.52%
2001 11.146.000 23.75%
2002 14.910.000 25.24%
2003 20.534.000 27.39%
2004 26.169.000 21.53%
2005 30.014.000 12.81%
2006 37.216.000 19.35%
2007 50.106.000 25.73%
2008 60.524.000 17.21%
2009 63.056.000 4.02%
2010 75.202.000 16.15%
2011 92.007.000 18.26%
2012 109.733.000 16.15%
2013 120.124.000 8.65%
2014 118.226.000 -1.61%
2015 114.865.000 -2.93%
2016 118.651.000 3.19%
2017 144.467.000 17.87%
2018 155.149.000 6.88%
2019 180.651.000 14.12%
2020 201.946.000 10.54%
2021 225.284.000 10.36%
2022 253.575.000 11.16%
2023 287.642.000 11.84%
2024 302.840.000 5.02%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ResMed Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 11.100.000 100%
1997 16.800.000 33.93%
1998 21.100.000 20.38%
1999 27.400.000 22.99%
2000 36.987.000 25.92%
2001 49.914.000 25.9%
2002 64.481.000 22.59%
2003 85.313.000 24.42%
2004 104.706.000 18.52%
2005 135.703.000 22.84%
2006 200.168.000 32.21%
2007 237.326.000 15.66%
2008 278.087.000 14.66%
2009 289.875.000 4.07%
2010 331.858.000 12.65%
2011 372.249.000 10.85%
2012 401.621.000 7.31%
2013 430.802.000 6.77%
2014 450.414.000 4.35%
2015 478.627.000 5.89%
2016 488.057.000 1.93%
2017 553.968.000 11.9%
2018 600.369.000 7.73%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ResMed Inc. EBITDA
Year EBITDA Growth
1993 300.000
1994 1.100.000 72.73%
1995 2.400.000 54.17%
1996 2.000.000 -20%
1997 8.100.000 75.31%
1998 22.300.000 63.68%
1999 31.400.000 28.98%
2000 39.159.000 19.81%
2001 67.807.000 42.25%
2002 -44.795.000 251.37%
2003 77.387.000 157.88%
2004 102.738.000 24.68%
2005 147.738.000 30.46%
2006 175.153.000 15.65%
2007 136.971.000 -27.88%
2008 204.384.000 32.98%
2009 203.203.000 -0.58%
2010 248.245.000 18.14%
2011 289.810.000 14.34%
2012 310.381.000 6.63%
2013 364.966.000 14.96%
2014 427.472.000 14.62%
2015 494.292.000 13.52%
2016 540.557.000 8.56%
2017 599.823.000 9.88%
2018 698.655.000 14.15%
2019 843.504.000 17.17%
2020 989.832.000 14.78%
2021 1.112.542.000 11.03%
2022 1.194.127.000 6.83%
2023 1.339.536.000 10.86%
2024 1.155.988.000 -15.88%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ResMed Inc. Gross Profit
Year Gross Profit Growth
1993 4.800.000
1994 8.000.000 40%
1995 12.800.000 37.5%
1996 18.900.000 32.28%
1997 31.500.000 40%
1998 47.100.000 33.12%
1999 63.800.000 26.18%
2000 84.872.000 24.83%
2001 104.779.000 19%
2002 133.249.000 21.37%
2003 173.087.000 23.02%
2004 216.736.000 20.14%
2005 274.860.000 21.15%
2006 376.895.000 27.07%
2007 384.492.000 1.98%
2008 493.750.000 22.13%
2009 553.802.000 10.84%
2010 655.483.000 15.51%
2011 741.326.000 11.58%
2012 820.735.000 9.68%
2013 940.657.000 12.75%
2014 989.786.000 4.96%
2015 1.011.396.000 2.14%
2016 1.066.497.000 5.17%
2017 1.201.745.000 11.25%
2018 1.362.164.000 11.78%
2019 1.536.585.000 11.35%
2020 1.717.786.000 10.55%
2021 1.839.100.000 6.6%
2022 2.024.311.000 9.15%
2023 2.355.662.000 14.07%
2024 2.400.240.000 1.86%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ResMed Inc. Net Profit
Year Net Profit Growth
1993 800.000
1994 1.200.000 33.33%
1995 2.800.000 57.14%
1996 4.500.000 37.78%
1997 7.500.000 40%
1998 10.600.000 29.25%
1999 16.100.000 34.16%
2000 22.226.000 27.56%
2001 11.630.000 -91.11%
2002 37.506.000 68.99%
2003 45.729.000 17.98%
2004 57.284.000 20.17%
2005 64.785.000 11.58%
2006 88.211.000 26.56%
2007 66.302.000 -33.04%
2008 110.303.000 39.89%
2009 146.448.000 24.68%
2010 190.085.000 22.96%
2011 226.986.000 16.26%
2012 254.850.000 10.93%
2013 307.133.000 17.02%
2014 345.273.000 11.05%
2015 352.886.000 2.16%
2016 352.408.000 -0.14%
2017 342.284.000 -2.96%
2018 315.588.000 -8.46%
2019 404.592.000 22%
2020 621.674.000 34.92%
2021 474.505.000 -31.02%
2022 779.437.000 39.12%
2023 897.556.000 13.16%
2024 877.688.000 -2.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ResMed Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 1 0%
2007 0 0%
2008 1 0%
2009 1 0%
2010 1 100%
2011 1 0%
2012 2 0%
2013 2 50%
2014 2 0%
2015 3 0%
2016 3 0%
2017 2 0%
2018 2 0%
2019 3 0%
2020 4 50%
2021 3 -33.33%
2022 5 40%
2023 6 16.67%
2024 6 -20%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ResMed Inc. Free Cashflow
Year Free Cashflow Growth
1993 700.000
1994 1.300.000 46.15%
1995 -1.100.000 218.18%
1996 2.000.000 155%
1997 5.500.000 63.64%
1998 -5.000.000 210%
1999 -4.300.000 -16.28%
2000 4.107.000 204.7%
2001 2.061.000 -99.27%
2002 7.455.000 72.35%
2003 33.649.000 77.84%
2004 19.295.000 -74.39%
2005 31.388.000 38.53%
2006 -3.721.000 943.54%
2007 13.550.000 127.46%
2008 62.057.000 78.17%
2009 124.657.000 50.22%
2010 126.572.000 1.51%
2011 208.194.000 39.2%
2012 322.052.000 35.35%
2013 331.041.000 2.72%
2014 310.112.000 -6.75%
2015 311.236.000 0.36%
2016 480.103.000 35.17%
2017 342.577.000 -40.14%
2018 433.569.000 20.99%
2019 381.709.000 -13.59%
2020 696.317.000 45.18%
2021 619.892.000 -12.33%
2022 195.111.000 -217.71%
2023 559.299.000 65.12%
2024 245.417.000 -127.9%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ResMed Inc. Operating Cashflow
Year Operating Cashflow Growth
1993 1.000.000
1994 1.600.000 37.5%
1995 700.000 -128.57%
1996 3.500.000 80%
1997 9.500.000 63.16%
1998 6.800.000 -39.71%
1999 18.200.000 62.64%
2000 20.275.000 10.23%
2001 29.520.000 31.32%
2002 35.640.000 17.17%
2003 59.284.000 39.88%
2004 76.541.000 22.55%
2005 71.079.000 -7.68%
2006 99.028.000 28.22%
2007 91.106.000 -8.7%
2008 137.836.000 33.9%
2009 238.877.000 42.3%
2010 188.213.000 -26.92%
2011 283.190.000 33.54%
2012 383.159.000 26.09%
2013 402.823.000 4.88%
2014 391.268.000 -2.95%
2015 383.180.000 -2.11%
2016 547.932.000 30.07%
2017 414.053.000 -32.33%
2018 505.026.000 18.01%
2019 459.051.000 -10.02%
2020 802.255.000 42.78%
2021 736.718.000 -8.9%
2022 351.147.000 -109.8%
2023 693.299.000 49.35%
2024 286.283.000 -142.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ResMed Inc. Capital Expenditure
Year Capital Expenditure Growth
1993 300.000
1994 300.000 0%
1995 1.800.000 83.33%
1996 1.500.000 -20%
1997 4.000.000 62.5%
1998 11.800.000 66.1%
1999 22.500.000 47.56%
2000 16.168.000 -39.16%
2001 27.459.000 41.12%
2002 28.185.000 2.58%
2003 25.635.000 -9.95%
2004 57.246.000 55.22%
2005 39.691.000 -44.23%
2006 102.749.000 61.37%
2007 77.556.000 -32.48%
2008 75.779.000 -2.34%
2009 114.220.000 33.66%
2010 61.641.000 -85.3%
2011 74.996.000 17.81%
2012 61.107.000 -22.73%
2013 71.782.000 14.87%
2014 81.156.000 11.55%
2015 71.944.000 -12.8%
2016 67.829.000 -6.07%
2017 71.476.000 5.1%
2018 71.457.000 -0.03%
2019 77.342.000 7.61%
2020 105.938.000 26.99%
2021 116.826.000 9.32%
2022 156.036.000 25.13%
2023 134.000.000 -16.44%
2024 40.866.000 -227.9%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ResMed Inc. Equity
Year Equity Growth
1993 2.900.000
1994 5.600.000 48.21%
1995 28.900.000 80.62%
1996 39.000.000 25.9%
1997 44.600.000 12.56%
1998 50.800.000 12.2%
1999 71.600.000 29.05%
2000 93.972.000 23.81%
2001 100.366.000 6.37%
2002 192.930.000 47.98%
2003 286.433.000 32.64%
2004 361.499.000 20.77%
2005 474.065.000 23.74%
2006 738.148.000 35.78%
2007 931.222.000 20.73%
2008 1.081.775.000 13.92%
2009 1.115.192.000 3%
2010 1.287.536.000 13.39%
2011 1.730.737.000 25.61%
2012 1.607.627.000 -7.66%
2013 1.610.516.000 0.18%
2014 1.758.248.000 8.4%
2015 1.587.307.000 -10.77%
2016 1.694.831.000 6.34%
2017 1.960.266.000 13.54%
2018 2.058.980.000 4.79%
2019 2.072.193.000 0.64%
2020 2.497.027.000 17.01%
2021 2.885.679.000 13.47%
2022 3.360.751.000 14.14%
2023 4.129.903.000 18.62%
2024 4.250.376.000 2.83%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ResMed Inc. Assets
Year Assets Growth
1993 5.200.000
1994 9.600.000 45.83%
1995 35.300.000 72.8%
1996 46.900.000 24.73%
1997 54.900.000 14.57%
1998 64.600.000 15.02%
1999 89.900.000 28.14%
2000 115.594.000 22.23%
2001 288.090.000 59.88%
2002 376.191.000 23.42%
2003 459.595.000 18.15%
2004 544.159.000 15.54%
2005 774.146.000 29.71%
2006 1.007.221.000 23.14%
2007 1.252.042.000 19.55%
2008 1.406.000.000 10.95%
2009 1.507.968.000 6.76%
2010 1.626.397.000 7.28%
2011 2.068.922.000 21.39%
2012 2.137.869.000 3.23%
2013 2.210.721.000 3.3%
2014 2.360.962.000 6.36%
2015 2.184.260.000 -8.09%
2016 3.258.935.000 32.98%
2017 3.468.487.000 6.04%
2018 3.063.923.000 -13.2%
2019 4.107.682.000 25.41%
2020 4.587.376.000 10.46%
2021 4.728.125.000 2.98%
2022 5.095.853.000 7.22%
2023 6.751.708.000 24.52%
2024 6.740.786.000 -0.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ResMed Inc. Liabilities
Year Liabilities Growth
1993 2.300.000
1994 4.000.000 42.5%
1995 6.400.000 37.5%
1996 7.900.000 18.99%
1997 10.300.000 23.3%
1998 13.800.000 25.36%
1999 18.300.000 24.59%
2000 21.622.000 15.36%
2001 187.724.000 88.48%
2002 183.261.000 -2.44%
2003 173.162.000 -5.83%
2004 182.660.000 5.2%
2005 300.081.000 39.13%
2006 269.073.000 -11.52%
2007 320.820.000 16.13%
2008 324.225.000 1.05%
2009 392.776.000 17.45%
2010 338.861.000 -15.91%
2011 338.185.000 -0.2%
2012 530.242.000 36.22%
2013 600.205.000 11.66%
2014 602.714.000 0.42%
2015 596.953.000 -0.97%
2016 1.564.104.000 61.83%
2017 1.508.221.000 -3.71%
2018 1.004.943.000 -50.08%
2019 2.035.489.000 50.63%
2020 2.090.349.000 2.62%
2021 1.842.446.000 -13.46%
2022 1.735.102.000 -6.19%
2023 2.621.805.000 33.82%
2024 2.490.410.000 -5.28%

ResMed Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
28.8
Net Income per Share
6.16
Price to Earning Ratio
28.58x
Price To Sales Ratio
6.12x
POCF Ratio
27.71
PFCF Ratio
32.7
Price to Book Ratio
6.1
EV to Sales
6.42
EV Over EBITDA
20.73
EV to Operating CashFlow
29.09
EV to FreeCashFlow
34.32
Earnings Yield
0.03
FreeCashFlow Yield
0.03
Market Cap
25,91 Bil.
Enterprise Value
27,20 Bil.
Graham Number
63.31
Graham NetNet
-8.72

Income Statement Metrics

Net Income per Share
6.16
Income Quality
1.03
ROE
0.23
Return On Assets
0.13
Return On Capital Employed
0.19
Net Income per EBT
0.81
EBT Per Ebit
0.96
Ebit per Revenue
0.26
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.57
Operating Profit Margin
0.26
Pretax Profit Margin
0.25
Net Profit Margin
0.2

Dividends

Dividend Yield
0.01
Dividend Yield %
1.04
Payout Ratio
0.29
Dividend Per Share
1.84

Operating Metrics

Operating Cashflow per Share
6.36
Free CashFlow per Share
5.39
Capex to Operating CashFlow
-0.15
Capex to Revenue
-0.03
Capex to Depreciation
-0.69
Return on Invested Capital
0.16
Return on Tangible Assets
0.27
Days Sales Outstanding
59.66
Days Payables Outstanding
35.49
Days of Inventory on Hand
192.09
Receivables Turnover
6.12
Payables Turnover
10.28
Inventory Turnover
1.9
Capex per Share
-0.97

Balance Sheet

Cash per Share
1,42
Book Value per Share
28,90
Tangible Book Value per Share
5.95
Shareholders Equity per Share
28.9
Interest Debt per Share
9.79
Debt to Equity
0.35
Debt to Assets
0.22
Net Debt to EBITDA
0.98
Current Ratio
2.99
Tangible Asset Value
0,87 Bil.
Net Current Asset Value
-0,19 Bil.
Invested Capital
0.35
Working Capital
1,53 Bil.
Intangibles to Total Assets
0.5
Average Receivables
0,70 Bil.
Average Payables
0,16 Bil.
Average Inventory
978122500
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ResMed Inc. Dividends
Year Dividends Growth
2012 0
2013 1 0%
2014 1 100%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 2 0%
2020 2 0%
2021 2 0%
2022 2 0%
2023 2 0%

ResMed Inc. Profile

About ResMed Inc.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

CEO
Mr. Michael J. Farrell BE, MBA
Employee
10.140
Address
9001 Spectrum Center Boulevard
San Diego, 92123

ResMed Inc. Executives & BODs

ResMed Inc. Executives & BODs
# Name Age
1 Mr. Kaushik Ghoshal
Chief Commercial Officer - SaaS
70
2 Mr. Michael J. Farrell BE, MBA, SM
Chief Executive Officer & Chairman
70
3 Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD
Founder, Chair Emeritus & Director
70
4 Mr. Robert A. Douglas
Special Advisor
70
5 Ms. Amy Wakeham
Chief Investor Relations Officer
70
6 Mr. Michael J. Rider
Chief Legal Officer
70
7 Mr. Jim Ellis
Chief Compliance Officer
70
8 Mr. Brett A. Sandercock
Chief Financial Officer
70
9 Ms. Yvonne-Katrin Pucknat
Chief Marketing Officer
70
10 Ms. Vered Keisar
Chief People Officer
70

ResMed Inc. Competitors